Long-term niraparib follow-up for people already benefiting
Treatments studied
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This study looks at continuing niraparib for a longer time in people who already finished an earlier niraparib trial and are still benefiting. It may help understand how safe and useful long-term treatment is for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and agree by signing written consent
- You can attend scheduled visits and follow the treatment plan
- You are currently taking niraparib from a prior GlaxoSmithKline/TESARO study, and that earlier study is finished
- Your doctor thinks you are still benefiting from niraparib in the earlier study
- You were not permanently stopped from niraparib in the earlier study
- If you can get pregnant (or have a partner who can), you must use effective birth control during treatment and for 180 days after your last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a medication called niraparib (Zejula) for women with advanced or relapsed ovarian cancer. It may help keep the cancer from coming back after it has responded to platinum-based chemotherapy. The study focuses on safety and is for women who meet certain health and treatment criteria.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
This Phase 2 study tests niraparib by itself to keep endometrial serous cancer from returning or to control it after chemotherapy helps. It may help some people by targeting tumor DNA repair weaknesses, especially in cancers with certain gene changes.
This trial tests whether taking niraparib (a maintenance anti-cancer pill) for a shorter time after 3 cycles of platinum chemotherapy works as well as taking it after 6 cycles. It is for people with advanced ovarian cancer that has been fully removed (no visible tumor) and is “HRD-positive,” meaning it has certain DNA repair weaknesses.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.